Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.3609) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Stock Up 8.1%

Shares of NASDAQ:AMLX opened at $21.81 on Wednesday. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of -14.54 and a beta of -0.21. The company’s fifty day simple moving average is $16.84 and its 200 day simple moving average is $15.58. Amylyx Pharmaceuticals has a 12 month low of $7.48 and a 12 month high of $22.28.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Citigroup boosted their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a research report on Monday, June 8th. Wall Street Zen cut shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Guggenheim raised their price objective on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, June 25th. Finally, Mizuho lifted their target price on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $25.38.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the sale, the insider owned 194,090 shares of the company’s stock, valued at $3,555,728.80. This trade represents a 7.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 10.90% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds have recently modified their holdings of AMLX. Ameriprise Financial Inc. raised its holdings in Amylyx Pharmaceuticals by 643.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 95,219 shares of the company’s stock valued at $610,000 after acquiring an additional 82,414 shares during the period. MetLife Investment Management LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 15.7% during the fourth quarter. MetLife Investment Management LLC now owns 49,654 shares of the company’s stock worth $600,000 after acquiring an additional 6,725 shares during the period. Intech Investment Management LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 64.2% during the fourth quarter. Intech Investment Management LLC now owns 32,006 shares of the company’s stock worth $387,000 after acquiring an additional 12,512 shares during the period. Persistent Asset Partners Ltd boosted its holdings in shares of Amylyx Pharmaceuticals by 35.9% during the fourth quarter. Persistent Asset Partners Ltd now owns 31,147 shares of the company’s stock worth $376,000 after acquiring an additional 8,234 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Amylyx Pharmaceuticals in the fourth quarter valued at approximately $369,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.